Cardiovascular Disease as a Long-Term Consideration in Lupus
Although lupus is often discussed in terms of immune and inflammatory activity, cardiovascular disease has emerged as a significant contributor to long-term health outcomes. Population studies have reported higher rates of myocardial infarction and other vascular events among people living with SLE, including younger individuals who would otherwise be considered low risk.
Researchers attribute this pattern to a combination of sustained inflammation, immune-related vascular changes, and the effects of certain treatments used over time. These findings have prompted closer examination of how cardiovascular health intersects with autoimmune disease rather than existing as a separate concern.
Factors Under Study in Lupus-Associated Cardiovascular Risk
The biological processes linked to cardiovascular disease in lupus extend beyond traditional risk factors. Ongoing research examines how immune activity, endothelial dysfunction, oxidative stress, and autoantibody profiles may influence vascular health.
Medication exposure is also part of this discussion. Some therapies used to manage lupus are associated with metabolic and vascular effects over time, while others are studied for their potential influence on lipid profiles and inflammation. These relationships are complex and vary across individuals and disease patterns.
Limitations of General Cardiovascular Risk Models
Standard cardiovascular risk calculators were developed for the general population and do not account for autoimmune-related inflammation or disease-specific factors. As a result, several studies suggest that these tools may underestimate cardiovascular risk in people with lupus.
Researchers have proposed alternative models that incorporate disease duration, inflammatory markers, and autoantibody status. These models remain under evaluation and are best understood as research tools rather than definitive predictors of individual outcomes.
Cardiovascular Health Within Multidisciplinary Care Discussions
In clinical literature, cardiovascular health in lupus is increasingly discussed as part of broader, multidisciplinary care conversations. Rather than focusing solely on event prevention, this perspective emphasizes long-term patterns, cumulative exposure, and coordination across specialties.
This approach reflects a growing recognition that cardiovascular outcomes are shaped by many interacting factors, including disease course, treatment history, access to care, and social context. No single strategy is positioned as universally applicable.
Reflecting on the Direction of Research
Current research underscores the need for continued exploration of how autoimmune activity and cardiovascular health intersect over time. While associations are well documented at the population level, translating these findings into individualized care remains complex.
As with many aspects of chronic illness, cardiovascular health in lupus is best understood through an evolving, contextual lens, one that prioritizes awareness, shared understanding, and ongoing inquiry rather than fixed targets or prescriptive pathways.
References
Drosos, G. C., Vedder, D., Houben, E., Boekel, L., Atzeni, F., Badreh, S., Boumpas, D. T., Brodin, N., Bruce, I. N., González-Gay, M. Á., Jacobsen, S., Kerekes, G., Marchiori, F., Mukhtyar, C., Ramos-Casals, M., Sattar, N., Schreiber, K., Sciascia, S., Svenungsson, E., Szekanecz, Z., … Tektonidou, M. G. (2022). EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the rheumatic diseases, 81(6), 768–779. https://doi.org/10.1136/annrheumdis-2021-221733
Ikram, N., Choi, M., Garshick, M. S., Costenbader, K., & Weber, B. (2025, February 5). Atherosclerotic cardiovascular disease risk prediction in systemic lupus erythematosus. American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Articles/2025/02/05/13/34/Atherosclerotic-Cardiovascular-Disease-Risk-Prediction-in-Systemic-Lupus-Erythematosus
Semalulu, T., Tago, A., Zhao, K., & Tselios, K. (2023). Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician. ImmunoTargets and therapy, 12, 175–186. https://doi.org/10.2147/ITT.S377076
Replies (0)
